Atorvastatin ( DrugBank: Atorvastatin )

---

19 diseases

告示番号	疾患名（ページ内リンク）	臨床試験数
13	多発性硬化症／視神経脊髄炎	8
46	悪性関節リウマチ	8
49	全身性エリテマトーデス	6
51	全身性強皮症	2
58	肥大型心筋症	1
63	特発性血小板減少性紫斑病	2
79	家族性高コレステロール血症（ホモ接合体）	3
84	サルコイドーシス	1
88	慢性血栓塞栓性肺高血圧症	1
93	原発性胆汁性胆管炎	2
96	クローン病	3
97	潰瘍性大腸炎	3
160	先天性魚鱗癬	1
222	一次性ネフローゼ症候群	1
225	先天性腎性尿崩症	1
265	脂肪萎縮症	1
271	強直性脊椎炎	1
297	アラジール症候群	1
299	嚢胞性線維症	4

13. 多発性硬化症／視神経脊髄炎

---

臨床試験数 : 3,340 /  薬物数 : 2,163 - (DrugBank : 383) / 標的遺伝子数 : 241 - 標的パスウェイ数 : 238

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT01111656 (ClinicalTrials.gov)	March 2007	15/3/2010	Efficacy, Safety and Tolerability of Atorvastatin 40 mg in Patients With Relapsing-remitting Multiple Sclerosis Treated With Interferon-beta-1b	SWiss Atorvastatin and Interferon-Beta 1b Trial In Multiple Sclerosis - Follow up Study (SWABIMS Follow Up-study)	Relapsing-remitting Multiple Sclerosis	Drug: Interferon beta-1b group;Drug: Interferon beta-1b/Atorvastatin group	University Hospital Inselspital, Berne	Viollier AG, Basel, Switzerland;PharmaPart GmbH, Thalwil, Switzerland	Completed	18 Years	67 Years	Both	28	Phase 2	Switzerland
2	NCT00818103 (ClinicalTrials.gov)	January 2006	31/12/2008	Characteristic Study on Chinese Patients With Multiple Sclerosis	Characteristic Study on Chinese Patients With Multiple Sclerosis	Multiple Sclerosis	Drug: atorvastatin;Drug: ß-interferon;Drug: EPO	Sun Yat-sen University	Third Affiliated Hospital, Sun Yat-Sen University	Recruiting	N/A	65 Years	Both	600	N/A	China
3	EUCTR2005-001009-25-IT (EUCTR)	16/07/2005	15/03/2006	Efficacy, safety and tolerability of Atorvastatin 40 mg in patients with Relapsing-remitting multIple sclerosis in treAtment with INterferoN-betA. - ARIANNA	Efficacy, safety and tolerability of Atorvastatin 40 mg in patients with Relapsing-remitting multIple sclerosis in treAtment with INterferoN-betA. - ARIANNA	Multiple sclerosis treatment MedDRA version: 14.1;Level: PT;Classification code 10028245;Term: Multiple sclerosis;System Organ Class: 10029205 - Nervous system disorders;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]	Trade Name: TORVAST*10CPR 10MG INN or Proposed INN: Atorvastatin Trade Name: TORVAST*10CPR 10MG INN or Proposed INN: Atorvastatin	DR DIMENSIONE RICERCA	NULL	Not Recruiting			Female: yes Male: yes			Italy
4	NCT00094172 (ClinicalTrials.gov)	May 2005	14/10/2004	Atorvastatin (Lipitor) Therapy in Patients With Clinically Isolated Syndrome (CIS) at Risk for Multiple Sclerosis	A Randomized, Double-Blind, Placebo-Controlled, Multi-Center Study to Evaluate the Efficacy and Safety of Atorvastatin in Patients With Clinically Isolated Syndrome and High Risk of Conversion to Multiple Sclerosis (ITN020AI)	Multiple Sclerosis	Drug: Atorvastatin;Drug: Placebo	National Institute of Allergy and Infectious Diseases (NIAID)	Immune Tolerance Network (ITN)	Completed	18 Years	55 Years	All	82	Phase 2	United States;Canada
5	NCT00942591 (ClinicalTrials.gov)	May 2005	17/7/2009	Atorvastatin 40 mg in Patients With Relapsing-Remitting Multiple Sclerosis Treated With Interferon-Beta-1b	Efficacy, Safety and Tolerability of Atorvastatin 40 mg in Patients With Relapsing-remitting Multiple Sclerosis Treated With Interferon-beta-1b.SWiss Atorvastatin and Interferon-Beta 1b Trial In Multiple Sclerosis.	Multiple Sclerosis	Drug: Interferon beta 1b;Drug: Atorvastatin	University Hospital Inselspital, Berne	CRO: PharmaPart AG, Bahnhofstrasse 20, P.O. Box 173, CH-8800 Thalwil;Laboratory: Viollier AG Spalenring 145 / 147 Postfach 4002 Basel	Completed	18 Years	55 Years	Both	77	Phase 2	Switzerland
6	NCT00137176 (ClinicalTrials.gov)	October 2004	26/8/2005	EARLY IFNb-1a and Atorvastatin Combination Therapy of Isolated Clinical Syndrome Suggestive of Multiple Sclerosis	EARLY IFNb-1a (Rebif) and Atorvastatin (Lipitor) Combination Therapy of Isolated Clinical Syndrome Suggestive of Multiple Sclerosis	Multiple Sclerosis	Drug: Rebif	University of North Carolina, Chapel Hill	NULL	Completed	18 Years	60 Years	Both	30	N/A	United States
7	NCT00103974 (ClinicalTrials.gov)	July 2004	17/2/2005	Immunotherapy With BHT-3009 Alone or Combined With Atorvastatin in Patients With Multiple Sclerosis	A Phase I Trial of Immunotherapy With BHT-3009 Alone or Combined With Atorvastatin in Patients With Multiple Sclerosis	Multiple Sclerosis	Biological: BHT-3009-01	Bayhill Therapeutics	NULL	Completed	18 Years	65 Years	Both	30	Phase 1	United States;Canada
8	NCT00616187 (ClinicalTrials.gov)	October 2003	5/2/2008	Atorvastatin in Relapsing-Remitting Multiple Sclerosis	Oral High-Dose Atorvastatin Treatment in Relapsing-Remitting Multiple Sclerosis	Relapsing Remitting Multiple Sclerosis	Drug: interferon beta treatment to add-on atorvastatin treatment;Drug: untreated to atorvastatin treatment	Charite University, Berlin, Germany	German Research Foundation;German Federal Ministry of Education and Research;Pfizer	Completed	18 Years	55 Years	All	41	Phase 2	NULL

先頭へ

46. 悪性関節リウマチ

---

臨床試験数 : 4,356 /  薬物数 : 2,567 - (DrugBank : 415) / 標的遺伝子数 : 192 - 標的パスウェイ数 : 228

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT04608344 (ClinicalTrials.gov)	November 4, 2020	23/10/2020	Study to Evaluate Organic Anion Transporting Polypeptide (OATP) Transporter-Mediated Drug-Drug Interactions Between Filgotinib and Statins as Probe Drugs in Healthy Participants	A Phase 1 Study to Evaluate OATP Transporter-Mediated Drug-Drug Interactions Between Filgotinib and Statins as Probe Drugs in Healthy Participants	Rheumatoid Arthritis	Drug: Atorvastatin;Drug: Pravastatin;Drug: Rosuvastatin;Drug: Filgotinib	Gilead Sciences	Galapagos NV	Completed	18 Years	55 Years	All	27	Phase 1	United States
2	NCT04056039 (ClinicalTrials.gov)	August 14, 2018	21/6/2019	Atorvastatin vs Colchicine in Decrease of Troponin I of High Sensitivity in Patients With Rheumatoid Arthritis.	Efficacy of Atorvastatin vs Colchicine in Decrease of Troponin I of High Sensitivity as a Biomarker of Myocardial Damage in Patients With Rheumatoid Arthritis With Severe Activity.	Cardiovascular Diseases;Arthritis, Rheumatoid	Drug: Atorvastatin;Drug: Colchicine	Hospital Central Dr. Ignacio Morones Prieto	NULL	Completed	18 Years	N/A	All	60	Phase 2	Mexico
3	ChiCTR-INR-17011772	2017-06-27	2017-06-28	Canceled by the investigator The efficacy and safety of metformin hydrochloride combined with atorvastatin in the treatment of rheumatoid arthritis with poor response to immunosuppressive agents	The efficacy and safety of metformin hydrochloride combined with atorvastatin in the treatment of rheumatoid arthritis with poor response to immunosuppressive agents	Rheumatoid Arthritis	test group:Metformin tablets, 0.25g, 3 / day, oral, atorvastatin tablets 10mg, 1 / night, oral;;Control group:Traditional DMARDs group;	Inner Mongolia University of Science and Technology Baotou Medical College First Affiliated Hospital	NULL	Recruiting	18	65	Both	test group:80;Control group:40;		China
4	EUCTR2013-005524-42-NL (EUCTR)	10/03/2015	27/03/2014	STAtins to Prevent Rheumatoid Arthritis (STAPRA)	Prevention of rheumatoid arthritis by atorvastatin in seropositive arthralgia patients: a multi-center doubleblind randomized placebo-controlled trial - STAtins to Prevent Rheumatoid Arthritis (STAPRA)	Rheumatoid arthritis MedDRA version: 19.0;Level: PT;Classification code 10039080;Term: Rheumatoid factor positive;System Organ Class: 10022891 - Investigations;Therapeutic area: Diseases [C] - Immune System Diseases [C20]	Trade Name: Atorvastatin Product Name: Atorvastatin Product Code: C10AA05 INN or Proposed INN: ATORVASTATIN	Reade	NULL	Not Recruiting			Female: yes Male: yes	220	Phase 4	Netherlands
5	NCT02219191 (ClinicalTrials.gov)	August 2014	16/7/2014	Puerarin Versus Atorvastatin in Treating Metabolism Syndrome in Patients With Chronic Rheumatic Diseases	The Effect of Puerarin Tablets in Treating Metabolism Syndrome in Patients With Chronic Rheumatic Diseases	Rheumatoid Arthritis	Drug: puerarin tablet 50 mg;Drug: Atorvastatin tablet 20 mg	Chengdu PLA General Hospital	NULL	Active, not recruiting	18 Years	75 Years	All	150	N/A	China
6	NCT01059864 (ClinicalTrials.gov)	February 2010	28/1/2010	Study Of The Effects Of Atorvastatin On Cholesterol Levels In Rheumatoid Arthritis Patients Taking CP-690,550	Phase 2 Study Of The Effects Of Open-Label CP-690,550 And Double-Blind Atorvastatin On Lipids In Patients With Active Rheumatoid Arthritis	Rheumatoid Arthritis	Drug: CP-690,550;Drug: Atorvastatin;Drug: Atorvastatin Placebo	Pfizer	NULL	Completed	18 Years	N/A	All	111	Phase 2	United States;Korea, Republic of
7	EUCTR2006-006032-22-GB (EUCTR)	04/04/2007	26/02/2007	TRial of Atorvastatin for the primary prevention of Cardiovascular Events in Rheumatoid Arthritis - TRACE RA	TRial of Atorvastatin for the primary prevention of Cardiovascular Events in Rheumatoid Arthritis - TRACE RA	Rheumatoid arthritis is associated with increased mortality from cardiovascular disease (CVD). Statins have a proven effect in reducing CVD events in at-risk populations, mostly due to their cholesterol-lowering properties, but possibly through anti-inflammatory and immunomodulatory effects. This trial will assess the hypothesis that atorvastatin is more effective than placebo in the primary prevention of cardiovascular events in patients with RA.	Product Name: Atorvastatin INN or Proposed INN: ATORVASTATIN	University of Manchester	Dudley Group of Hospitals NHS Trust	Not Recruiting			Female: yes Male: yes	5350	Human pharmacology (Phase 1): no Therapeutic exploratory (Phase 2): no Therapeutic confirmatory - (Phase 3): yes Therapeutic use (Phase 4): no	United Kingdom
8	NCT00356473 (ClinicalTrials.gov)	March 2003	25/7/2006	Effects of Atorvastatin on Disease Activity and HDL Cholesterol Function in Patients With Rheumatoid Arthritis	Effects of Atorvastatin on Disease Activity and HDL Cholesterol Anti-inflammatory Properties in Patients With Rheumatoid Arthritis	Rheumatoid Arthritis	Drug: Atorvastatin	University of California, Los Angeles	NULL	Completed	18 Years	N/A	Both	20	Phase 4	NULL

先頭へ

49. 全身性エリテマトーデス

---

臨床試験数 : 993 /  薬物数 : 702 - (DrugBank : 184) / 標的遺伝子数 : 116 - 標的パスウェイ数 : 200

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	ChiCTR-INC-17011497	2017-05-25	2017-05-26	Canceled by the investigator The efficacy and safety of metformin hydrochloride combined with atorvastatin in the treatment of moderate to severe activity systemic lupus erythematosus	The efficacy and safety of metformin hydrochloride combined with atorvastatin in the treatment of moderate to severe activity systemic lupus erythematosus	moderate to severe active systemic lupus erythematosus	Immunomodulation combined with traditional DMARDS treatment group:Immunomodulation combined with traditional DMARDS group: On the basis of glucocorticoid and traditional DMARDS treatment, metformin hydrochloride tablets 250mg, 3 times / day, oral; atorvastatin tablets 10mg, 1 times / day; in the first 4 weeks , 12 weeks and 24 weeks to assess the SELSNA-SLEDAI score table,traditional DMARDS treatment group:Traditional DMARDS treatment group: the use of glucocorticoid and traditional DMARDS treatment. The SELSNA-SLEDAI score table, BILAG worksheet, SLE damage index score were assessed at week 4, week 12 and week 24, and serum Th17, Treg and Th17 / Treg ratios were measured.;	The First Affiliated Hospital of Baotou Medical College, Inner Mongolia University of Science and Technology	NULL	Pending			Both	Immunomodulation combined with traditional DMARDS treatment group:60;traditional DMARDS treatment group:60;		China
2	ChiCTR-INR-17011495	2017-05-25	2017-05-26	Canceled by the investigator The efficacy and safety of metformin hydrochloride combined with atorvastatin in the treatment of primary mild to moderate systemic sy	The efficacy and safety of metformin hydrochloride combined with atorvastatin in the treatment of primary mild to moderate systemic systemic lupus erythematosus	Primary mild to moderate systemic systemic lupus erythematosus	Immunomodulatory treatment group:The level of SELSNA-SLEDAI was evaluated at week 4, week 12 and week 24, the BILAG table, the SLE lesion index, and the SLE damage index were measured at 4 weeks, 12 weeks and 24 weeks. The levels of Th17, Treg and Th17 / Treg were measured.;Leflunomide treatment group:Leflunomide tablets 10m, 1 times / day, orally. The SELSNA-SLEDAI score table, BILAG worksheet, SLE damage index score were assessed at week 4, week 12 and week 24, and serum Th17, Treg and Th17 / Treg ratios were measured.;Immunomodulatory treatment group and Leflunomide treatment group :0 weeks to give prednisone acetate tablets 0.5-1mg / kg.d (or patients can choose to take the same dose of methylprednisolone tablets), 4 weeks after the beginning of the dose by 2 weeks to reduce the regular dose of 10% Reduction to prednisone acetate tablets 10mg / day to maintain.;Immunomodulatory treatment group and Leflunomide treatment group:All patients without contraindications plus hydroxychloroquine tablets 0.2,2 / day, orally; and according to the condition plus calcium (800-1200mg / day), vitamin D (200-800IU / day) and other treatment.;	The First Affiliated Hospital of Baotou Medical College, Inner Mongolia University of Science and Technology	NULL	Recruiting			Both	Immunomodulatory treatment group:15;Leflunomide treatment group:15;Immunomodulatory treatment group and Leflunomide treatment group :30;Immunomodulatory treatment group and Leflunomide treatment group:30;		China
3	NCT00519363 (ClinicalTrials.gov)	September 2007	20/8/2007	Statins and Lupus: Effects of Statins on Clinical Lupus Parameters, Serological Markers and Toll-like Receptors	Statins and Lupus: Effects of Statins on Clinical Lupus Parameters, Serological Markers and Toll-like Receptors.	Systemic Lupus Erythematosus	Drug: atorvastatin	The Center for Rheumatic Disease, Allergy, & Immunology	Saint Luke's Health System	Completed	18 Years	60 Years	Female	15	Phase 1/Phase 2	United States
4	NCT00432354 (ClinicalTrials.gov)	March 2007	6/2/2007	An Open Labeled Pilot Study of Atorvastatin in Systemic Lupus Erythematosus		Systemic Lupus Erythematosus	Drug: atorvastatin	Buddhist Tzu Chi General Hospital	Pfizer	Recruiting	16 Years	80 Years	Both	40	Phase 2/Phase 3	Taiwan
5	NCT00412841 (ClinicalTrials.gov)	November 2002	18/12/2006	Atorvastatin to Prevent Avascular Necrosis of Bone in Steroid Treated Exacerbated Systemic Lupus Erythematosus	AVN Prevention With Lipitor in Lupus Erythematosus APLLE Trial	Avascular Necrosis	Drug: Atorvastatin;Procedure: MRI, Venipuncture;Drug: Placebo	NYU Langone Health	NULL	Terminated	18 Years	75 Years	Female	43	Phase 2	United States
6	NCT00120887 (ClinicalTrials.gov)	April 2002	12/7/2005	Lupus Atherosclerosis Prevention Study	Lupus Atherosclerosis Prevention Study	Systemic Lupus Erythematosus	Drug: Atorvastatin	Johns Hopkins University	Alliance for Lupus Research	Completed	18 Years	N/A	Both	200	Phase 4	United States

先頭へ

51. 全身性強皮症

---

臨床試験数 : 525 /  薬物数 : 565 - (DrugBank : 148) / 標的遺伝子数 : 114 - 標的パスウェイ数 : 217

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT02370784 (ClinicalTrials.gov)	February 2015	26/1/2015	Atorvastatin for Microvascular Endothelial Function and Raynaud in Early Diffuse Scleroderma	The Effect of Atorvastatin on Microvascular Endothelial Function and Raynaud in Early Diffuse Systemic Sclerosis	Scleroderma	Drug: atorvastatin;Drug: Placebo	Robyn T. Domsic, MD, MPH	National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)	Completed	18 Years	70 Years	All	24	Phase 2	United States
2	EUCTR2005-003775-21-GB (EUCTR)	14/08/2008	10/11/2005	Effects of atorvastatin on microcirculatory endothelial function in patients with systemic sclerosis - Atorvastatin in systemic sclerosis	Effects of atorvastatin on microcirculatory endothelial function in patients with systemic sclerosis - Atorvastatin in systemic sclerosis	Systemic sclerosis (also termed 'scleroderma')	Trade Name: Lipitor Product Name: Lipitor	Salford Royal Hospitals NHS Trust	University of Manchester	Not Recruiting			Female: yes Male: yes	36	Human pharmacology (Phase 1): no Therapeutic exploratory (Phase 2): no Therapeutic confirmatory - (Phase 3): no Therapeutic use (Phase 4): yes	United Kingdom

58. 肥大型心筋症

---

臨床試験数 : 126 /  薬物数 : 135 - (DrugBank : 42) / 標的遺伝子数 : 46 - 標的パスウェイ数 : 162

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT00317967 (ClinicalTrials.gov)	April 2007	24/4/2006	Study to Determine if Atorvastatin Reduces Size and Stiffness of Muscle in the Left Ventricle of the Heart	Statin Induced Regression of Cardiomyopathy Trial - SirCat	Hypertrophic Cardiomyopathy	Drug: Atorvastatin;Drug: Placebo	University of Calgary	Heart and Stroke Foundation of Canada	Completed	18 Years	N/A	Both	22	Phase 3	Canada

63. 特発性血小板減少性紫斑病

---

臨床試験数 : 391 /  薬物数 : 235 - (DrugBank : 50) / 標的遺伝子数 : 49 - 標的パスウェイ数 : 139

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT03692754 (ClinicalTrials.gov)	November 1, 2021	29/9/2018	Atorvastatin in Management of Newly Diagnosed ITP	A Single-center Prospective Randomized Study of Atorvastatin in the Treatment of Newly Diagnosed Primary Immune Thrombocytopenia (ITP)	Immune Thrombocytopenia;Purpura, Thrombocytopenic	Drug: Atorvastatin 20mg;Drug: Atorvastatin 10mg;Drug: Dexamethasone	Shandong University	NULL	Not yet recruiting	18 Years	80 Years	All	30	Phase 2/Phase 3	China
2	NCT05551624 (ClinicalTrials.gov)	July 4, 2018	20/9/2022	Evaluation of the Effect in Platelet Count of Atorvastatin and N-acetyl Cysteine	Evaluation of the Effect in Platelet Count of Atorvastatin and N-acetyl Cysteine in Patients With Primary Immune Thrombocytopenia Resistant to Steroid Treatment or in Relapse: An Exploratory Clinical Trial	Primary Immune Thrombocytopenia	Drug: Atorvastatin 40 Mg Oral Tablet + N-acetylcysteine 400 mg Oral tablet	Hospital Civil de Guadalajara	NULL	Completed	15 Years	N/A	All	15	Early Phase 1	Mexico

79. 家族性高コレステロール血症（ホモ接合体）

---

臨床試験数 : 145 /  薬物数 : 114 - (DrugBank : 26) / 標的遺伝子数 : 8 - 標的パスウェイ数 : 17

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT03510715 (ClinicalTrials.gov)	August 31, 2018	18/4/2018	An Efficacy and Safety Study of Alirocumab in Children and Adolescents With Homozygous Familial Hypercholesterolemia	An Open-Label Study to Evaluate the Efficacy and Safety of Alirocumab in Children and Adolescents With Homozygous Familial Hypercholesterolemia	Hypercholesterolemia	Drug: Alirocumab SAR236553 (REGN727);Drug: Rosuvastatin;Drug: Ezetimibe;Drug: Cholestyramine;Drug: Nicotinic acid;Drug: Fenofibrate;Drug: Omega-3 fatty acids;Drug: Atorvastatin;Drug: Simvastatin;Drug: Fluvastatin;Drug: Pravastatin;Drug: Lovastatin	Sanofi	Regeneron Pharmaceuticals	Completed	8 Years	17 Years	All	18	Phase 3	Brazil;Canada;Denmark;Mexico;Netherlands;Russian Federation;Slovenia;Spain;Taiwan;Turkey;Austria;France;Italy;Norway;United States
2	NCT03885921 (ClinicalTrials.gov)	October 25, 2000	20/3/2019	Safety and Tolerability Study of Ezetimibe (SCH 058235/MK-0653) Plus Atorvastatin or Simvastatin in Homozygous Familial Hypercholesterolemia (P01417/MK-0653-019)	Long-Term, Open-Label, Safety and Tolerability Study of SCH 58235 in Addition to Atorvastatin or Simvastatin in the Therapy of Homozygous Familial Hypercholesterolemia	Hypercholesterolemia	Drug: Ezetimibe;Drug: Atorvastatin;Drug: Simvastatin	Organon and Co	NULL	Completed	12 Years	N/A	All	44	Phase 3	NULL
3	NCT03884452 (ClinicalTrials.gov)	May 3, 2000	6/3/2019	Ezetimibe (SCH 58235) Taken With Either Atorvastatin or Simvastatin in Participants With Familial Hypercholesterolemia (MK-0653-018)	A Phase III Efficacy And Safety Study of Ezetimibe (SCH58235) 10 mg in Addition to Atorvastatin or Simvastatin in the Therapy of Homozygous Familial Hypercholesterolemia	Familial Hypercholesterolemia	Drug: Atorvastatin;Drug: Simvastatin;Drug: Ezetimibe;Drug: Placebo for Ezetimibe	Organon and Co	NULL	Completed	12 Years	N/A	All	50	Phase 3	NULL

84. サルコイドーシス

---

臨床試験数 : 149 /  薬物数 : 202 - (DrugBank : 78) / 標的遺伝子数 : 66 - 標的パスウェイ数 : 169

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT00279708 (ClinicalTrials.gov)	January 2006	18/1/2006	Atorvastatin to Treat Pulmonary Sarcoidosis	Atorvastatin as a Disease Modifying Agent in Stage II and III Pulmonary Sarcoidosis: A Randomized, Double-Blind, Placebo-Controlled Trial	Sarcoidosis, Pulmonary	Drug: Atorvastatin;Other: Placebo Oral Tablet	National Heart, Lung, and Blood Institute (NHLBI)	NULL	Completed	18 Years	70 Years	All	55	Phase 2	United States

88. 慢性血栓塞栓性肺高血圧症

---

臨床試験数 : 157 /  薬物数 : 107 - (DrugBank : 22) / 標的遺伝子数 : 14 - 標的パスウェイ数 : 54

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	ChiCTR-TNRC-08000263	2008-06-01	2008-12-18	The study of the intervention with statin on PE and CTEPH	The study of the intervention with statin on PE and CTEPH	pulmonary embolism and chronic thromboembolic pulmonary hypertension	Group A:basic treatment + atorvastatin;Group B:basic treatment;	Tongji Hospital of Tongji University	NULL	Completed	18	80	Both	Group A:30;Group B:30;		China

93. 原発性胆汁性胆管炎

---

臨床試験数 : 298 /  薬物数 : 252 - (DrugBank : 59) / 標的遺伝子数 : 35 - 標的パスウェイ数 : 115

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT00844402 (ClinicalTrials.gov)	January 2006	13/2/2009	Safety and Efficacy of Long-Term Treatment With Atorvastatin in Patients With Primary Biliary Cirrhosis	Safety and Efficacy of Long-Term Treatment With Atorvastatin in Patients With Primary Biliary Cirrhosis	Primary Biliary Cirrhosis;Hypercholesterolemia	Drug: Atorvastatin	Medical University of Graz	NULL	Completed	18 Years	70 Years	Both	40	Phase 3	Austria
2	EUCTR2005-002160-28-AT (EUCTR)	23/09/2005	19/08/2005	Safety and efficacy of long-term treatment with atorvastatin in patients with primary biliary cirrhosis	Safety and efficacy of long-term treatment with atorvastatin in patients with primary biliary cirrhosis	Reduction of cardiovascular risk may become key for the management of PBC. Therefore information on safety and efficacy (lipid-lowering effects) of statins in chronic cholestatic disorders is essential. Moreover, the study will answer the open question whether long-term treatment with statins may have potential beneficial effects on the course of PBC.	Trade Name: Sortis Product Name: Sortis 10 mg INN or Proposed INN: Atorvastatin	Medical University Graz,Department of Internal Medicine, Division of Gastroenterology and Hepatology	NULL	Not Recruiting			Female: yes Male: yes	80		Austria

96. クローン病

---

臨床試験数 : 2,442 /  薬物数 : 1,278 - (DrugBank : 248) / 標的遺伝子数 : 142 - 標的パスウェイ数 : 209

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	EUCTR2009-010163-16-GB (EUCTR)	05/06/2009	18/08/2009	Bile salt manipulation as a novel treatment for Crohn’s disease: a single centre open label pilot study of atorvastatin and colesevalam in patients with active ileal Crohn’s disease - Bile salt manipulation in Crohn’s disease	Bile salt manipulation as a novel treatment for Crohn’s disease: a single centre open label pilot study of atorvastatin and colesevalam in patients with active ileal Crohn’s disease - Bile salt manipulation in Crohn’s disease	Active Crohn's disease affecting the ileum MedDRA version: 9.1;Level: LLT;Classification code 10011406;Term: Crohn's ileitis MedDRA version: 9.1;Classification code 10058815;Term: Crohn's disease acute episode	Trade Name: Lipitor Trade Name: Cholestagel	University College London	NULL	Not Recruiting			Female: yes Male: yes	13	Human pharmacology (Phase 1): no Therapeutic exploratory (Phase 2): yes Therapeutic confirmatory - (Phase 3): no Therapeutic use (Phase 4): no	United Kingdom
2	EUCTR2005-000496-17-SE (EUCTR)	06/10/2006	24/02/2005	Atorvastatin in moderat active Crohns disease	Atorvastatin in moderat active Crohns disease	Crohn's disease is an idiopathic chronic inflammatory bowel disease thought to result from inappropriate and ongoing activation of the mucosal immune system driven by the presence of normal luminal flora. It may affect the hole gastrointestinal tract, from mouth to rectum, with symptoms such as diarrhea, weight lose, malabsorption, abdominal pain and fever.	Product Name: atorvastatin	Region Skåne	NULL	Not Recruiting			Female: yes Male: yes	12		Sweden
3	NCT00454545 (ClinicalTrials.gov)	October 2006	29/3/2007	Atorvastatin in Moderate Active Crohns Disease		Crohns Disease	Drug: Atorvastatin	Skane University Hospital	NULL	Completed	18 Years	65 Years	Both	12	Phase 2	Sweden

97. 潰瘍性大腸炎

---

臨床試験数 : 2,630 /  薬物数 : 1,459 - (DrugBank : 265) / 標的遺伝子数 : 144 - 標的パスウェイ数 : 202

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT05567068 (ClinicalTrials.gov)	February 1, 2023	1/10/2022	Atorvastatin Efficacy and Safety in Patients With Ulcerative Colitis	Repurposing Atorvastatin in Patients With Ulcerative Colitis Treated With Mesalamine by Modulation of mTOR/NLRP3 Pathway.	Inflammatory Bowel Diseases	Drug: Atorvastatin 80mg;Drug: Mesalamine	Tanta University	NULL	Not yet recruiting	18 Years	75 Years	All	44	Phase 2	NULL
2	NCT05561062 (ClinicalTrials.gov)	December 1, 2022	27/9/2022	Atorvastatin in Patients With Ulcerative Colitis	Combination of Atorvastatin and Mesalazine to Enhance Anti-inflammatory Effects and Attenuates Progression of Ulcerative Colitis	Inflammatory Bowel Diseases	Drug: Atorvastatin 80mg	Tanta University	NULL	Not yet recruiting	18 Years	75 Years	All	50	Phase 2	NULL
3	NCT04767984 (ClinicalTrials.gov)	September 24, 2021	23/2/2021	Testing Atorvastatin to Lower Colon Cancer Risk in Longstanding Ulcerative Colitis	A Randomized and Placebo-Controlled Phase II Trial Targeting Dominant-Negative Missense Mutant P53 by Atorvastatin for Reducing the Risk of Longstanding Ulcerative Colitis-Associated Cancer	Colorectal Carcinoma;Ulcerative Colitis	Drug: Atorvastatin Calcium;Procedure: Biopsy of Colon;Procedure: Biospecimen Collection;Drug: Placebo Administration;Other: Questionnaire Administration	National Cancer Institute (NCI)	NULL	Recruiting	18 Years	70 Years	All	70	Phase 2	United States

160. 先天性魚鱗癬

---

臨床試験数 : 42 /  薬物数 : 71 - (DrugBank : 21) / 標的遺伝子数 : 18 - 標的パスウェイ数 : 112

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	JPRN-jRCTs031180409	25/12/2013	22/03/2019	Treatment of the genetic defect of cholesterol biosynthetic pathway.	Treatment of the genetic defect of cholesterol biosynthetic pathway by the topical application of statin and cholesterol.	CHILD syndrome, Conradi syndrome, porokeratosis, atopic dermatitis, psoriasis, seborrheic dermatitis Dermatitis and eczema	To patients, 1% atorvastatin/ 2% cholesterol lotion and/or 1% atorvastatin/ 2% cholesterol ointment, and/or 1% oxiconazole cream are topically applied on the skin. To healthy subjects, administration of atorvastatin or topical application of 1% atorvastatin/ 2% cholesterol is performed once to investigate drug metabolism.	Kubo Akiharu	NULL	Complete	Not applicable	Not applicable	Both	158	Phase 2	Japan

222. 一次性ネフローゼ症候群

---

臨床試験数 : 310 /  薬物数 : 295 - (DrugBank : 117) / 標的遺伝子数 : 63 - 標的パスウェイ数 : 194

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT00814255 (ClinicalTrials.gov)	December 2008	22/12/2008	Novel Therapies for Resistant FSGS (FONTII): Phase II Clinical Trial	Novel Therapies for Resistant Focal Segmental Glomerulosclerosis	Focal Segmental Glomerulosclerosis	Drug: Adalimumab;Drug: Lisinopril, losartan, and atorvastatin;Drug: galactose	New York University School of Medicine	University of Michigan;The Cleveland Clinic;National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)	Completed	1 Year	65 Years	All	32	Phase 2	United States;Canada

225. 先天性腎性尿崩症

---

臨床試験数 : 15 /  薬物数 : 48 - (DrugBank : 18) / 標的遺伝子数 : 31 - 標的パスウェイ数 : 65

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT02967653 (ClinicalTrials.gov)	July 13, 2017	15/11/2016	Atorvastatin for the Treatment of Lithium-Induced Nephrogenic Diabetes Insipidus	Atorvastatin for the Treatment of Lithium-Induced Nephrogenic Diabetes Insipidus: A Randomized Controlled Trial	Lithium Use, Nephrogenic Diabetes Insipidus	Drug: Atorvastatin	Lady Davis Institute	NULL	Completed	18 Years	85 Years	All	60	Phase 2	Canada

265. 脂肪萎縮症

---

臨床試験数 : 112 /  薬物数 : 155 - (DrugBank : 55) / 標的遺伝子数 : 25 - 標的パスウェイ数 : 97

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT00017758 (ClinicalTrials.gov)	June 2001	11/6/2001	The Effect of Efavirenz and Nelfinavir on the Blood Levels of Certain Lipid-Lowering Drugs	The Effect of Efavirenz and Nelfinavir on the Pharmacokinetics of Hydroxymethylglutaryl Coenzyme A Reductase Inhibitors	HIV Infections;HIV Seronegativity;Lipodystrophy	Drug: Pravastatin sodium;Drug: Simvastatin;Drug: Atorvastatin calcium;Drug: Nelfinavir mesylate;Drug: Efavirenz	National Institute of Allergy and Infectious Diseases (NIAID)	NULL	Completed	18 Years	60 Years	Both	56	Phase 1	United States

271. 強直性脊椎炎

---

臨床試験数 : 574 /  薬物数 : 359 - (DrugBank : 68) / 標的遺伝子数 : 41 - 標的パスウェイ数 : 146

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	EUCTR2013-002860-19-NL (EUCTR)	07/01/2014	15/08/2013	Cardiovascular risk in patients with Ankylosing Spondylitis	The risk of cardiovascular disease in Ankylosing Spondylitis; A Single Center Cross-Sectional Study Evaluating The Association Between Inflammation In Ankylosing Spondylitis And Vascular Inflammation - AS risk	Ankylosing SpondylitisAtherosclerotic cardiovascular disease;Therapeutic area: Diseases [C] - Immune System Diseases [C20]	Trade Name: Atorvastatin Product Name: Atorvastatin Product Code: 5057732 INN or Proposed INN: ATORVASTATIN Other descriptive name: atorvastatin	AMC	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes			Netherlands

297. アラジール症候群

---

臨床試験数 : 45 /  薬物数 : 21 - (DrugBank : 10) / 標的遺伝子数 : 3 - 標的パスウェイ数 : 5

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT05488067 (ClinicalTrials.gov)	March 22, 2022	1/8/2022	Atorvastatin Therapy on Xanthoma in Alagille Syndrome	The Safety and Efficacy of Atorvastatin on Xanthoma in Alagille Syndrome	Alagille Syndrome;Atorvastatin;Xanthoma	Drug: atorvastatin	Children's Hospital of Fudan University	NULL	Recruiting	1 Day	17 Years	All	10	Phase 4	China

299. 嚢胞性線維症

---

臨床試験数 : 1,695 /  薬物数 : 1,527 - (DrugBank : 268) / 標的遺伝子数 : 111 - 標的パスウェイ数 : 174

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	EUCTR2010-022042-24-GB (EUCTR)	24/12/2010	25/10/2010	A Randomised Controlled Trial of Atorvastatin as an Anti-Inflammatory Agent in Non-Cystic Fibrosis Bronchiectasis in patients with Pseudomonas Aeruginosa - RCT of Atorvastatin in Bronchiectasis in patients with Pseudomonas	A Randomised Controlled Trial of Atorvastatin as an Anti-Inflammatory Agent in Non-Cystic Fibrosis Bronchiectasis in patients with Pseudomonas Aeruginosa - RCT of Atorvastatin in Bronchiectasis in patients with Pseudomonas	The aim of this randomized double blind controlled study is to evaluate the efficacy of a 3 months treatment with atorvastatin versus placebo in patients with clinically significant bronchiectasis. MedDRA version: 14.1;Level: PT;Classification code 10006445;Term: Bronchiectasis;System Organ Class: 10038738 - Respiratory, thoracic and mediastinal disorders	Trade Name: Lipitor Product Name: Atorvastatin INN or Proposed INN: Atorvastatin Other descriptive name: Lipitor	NHS Lothian	University of Edinburgh	Not Recruiting			Female: yes Male: yes	32	Phase 4	United Kingdom
2	EUCTR2010-022040-20-GB (EUCTR)	17/12/2010	21/10/2010	A Randomised Controlled Trial of Atorvastatin as an Anti-Inflammatory Agent in Non-Cystic Fibrosis Bronchiectasis - Randomised Controlled Trial of Atorvastatin in Bronchiectasis	A Randomised Controlled Trial of Atorvastatin as an Anti-Inflammatory Agent in Non-Cystic Fibrosis Bronchiectasis - Randomised Controlled Trial of Atorvastatin in Bronchiectasis	The aim of this randomised double blind controlled study to evaluate the efficacy of 6 months treatment with atorvastatin versus placebo in patients with clinically significant bronchiectasis MedDRA version: 14.1;Level: PT;Classification code 10006445;Term: Bronchiectasis;System Organ Class: 10038738 - Respiratory, thoracic and mediastinal disorders	Trade Name: Lipitor Product Name: Atorvastatin INN or Proposed INN: Atorvastatin Other descriptive name: Lipitor	NHS Lothian	University of Edinburgh	Not Recruiting			Female: yes Male: yes	60	Human pharmacology (Phase 1): no Therapeutic exploratory (Phase 2): no Therapeutic confirmatory - (Phase 3): no Therapeutic use (Phase 4): yes	United Kingdom
3	NCT01299181 (ClinicalTrials.gov)	November 2010	21/10/2010	A Trial of Atorvastatin as an Anti-Inflammatory Agent in Non-Cystic Fibrosis Bronchiectasis	A Randomised Controlled Trial of Atorvastatin as an Anti-Inflammatory Agent in Non-Cystic Fibrosis Bronchiectasis	Bronchiectasis	Drug: Atorvastatin	University of Edinburgh	NHS Lothian	Completed	18 Years	75 Years	Both	60	Phase 4	United Kingdom
4	NCT01299194 (ClinicalTrials.gov)	November 2010	21/10/2010	Atorvastatin in Bronchiectasis in Patients With Pseudomonas Aeruginosa	A Randomised Controlled Trial of Atorvastatin as an Anti-Inflammatory Agent in Non-Cystic Fibrosis Bronchiectasis in Patients With Pseudomonas Aeruginosa	BRONCHIECTASIS	Drug: ATORVASTATIN	University of Edinburgh	NHS Lothian	Completed	18 Years	80 Years	All	32	Phase 4	United Kingdom

先頭へ